Results 121 to 130 of about 101,548 (353)
GLP-1 and Its Role in Glycogen Production: A Narrative Review
BiomedicinesGlucagon-like peptide-1 (GLP-1) has emerged as a pivotal regulator in the management of glucose homeostasis, glycogen metabolism, and energy balance, positioning it as a critical therapeutic target for addressing obesity, metabolic syndrome, and type 2 ...
Joseph Lotosky +8 more
doaj +1 more source
Integrating the inputs that shape pancreatic islet hormone release. [PDF]
, 2019 The pancreatic islet is a complex mini organ composed of a variety of endocrine cells and their support cells, which together tightly control blood glucose homeostasis.
Huising, Mark O, Noguchi, Glyn M
core
Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies [PDF]
, 2013 BACKGROUND: Lixisenatide is a glucagon-like peptide-1 analog which stimulates insulin secretion and inhibits glucagon secretion and gastric emptying.
BP Bullock +35 more
core +3 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi +6 more
wiley +1 more source
Molecular regulation of hormone secretion, growth and apoptosis of GLP-1-producing cells [PDF]
, 2013 Type 2 diabetes (T2D) spreads like an epidemic in today’s society, and there is a great need for new and improved treatments. T2D is characterized by hyperglycemia, resulting from impaired insulin production and insulin resistance in peripheral ...
Kappe, Camilla
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1386-1397, April 2025.Sequeira et al. reveal how the glucagon‐like peptide‐1 receptor agonist (GLP‐1‐RA) semaglutide restores cardiomyocyte function in rats subjected to a high‐fat/high‐fructose diet (HFD). Employing fluorescence‐ and patch‐clamp technology in isolated cardiac myocytes, they demonstrate that semaglutide reverses HFD‐induced activation of L‐type calcium ...
Vasco Sequeira +12 more
wiley +1 more source
mAbs, 2020 The long circulating half-life and inherently bivalent architecture of IgGs provide an ideal vehicle for presenting otherwise short-lived G-protein-coupled receptor agonists in a format that enables avidity-driven enhancement of potency.
Raul C. Camacho +27 more
doaj +1 more source
Development of therapeutics for the treatment of diabetic brain complications [PDF]
, 2014 Type-2 diabetes (T2D) is characterized by hyperglycemia and hyperlipidemia, resulting in impaired insulin production and insulin resistance in peripheral tissues.
Mansouri, Shiva
core +1 more source
Journal of DiabetesAbstractGlucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have gained increasing attention for their potential benefits in people with type 2 diabetes mellitus (T2DM) with chronic kidney disease (CKD). Most supportive evidence of a kidney‐protective effect of the GLP‐1RA class of medications has been derived from kidney‐related outcomes reported ...
Richard J. MacIsaac +2 more
openaire +3 more sources
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source